一株有抑菌活性解淀粉芽孢杆菌的鉴定

为了研究环境中芽孢杆菌对常见细菌的抑菌能力,从池塘底泥中分离出6株芽孢杆菌进行了鉴定和抗菌能力研究。以大肠杆菌、金黄色葡萄球菌、藤黄微球菌和嗜水气单胞菌为研究对象,采用管碟法测定了细菌发酵上清液的抑菌活性,测定了发酵上清液和病原菌共培养的生长曲线,并采用生化和16S rRNA基因序列分析对细菌进行鉴定。结果发现其中1个菌株的发酵上清液对嗜水气单胞菌和藤黄微球菌的生长具有抑制作用,进一步通过生化和分子鉴定发现该菌株为解淀粉芽孢杆菌。结果表明:分离的解淀粉芽孢杆菌的发酵产物对嗜水气单胞菌和藤黄微球菌具有抑制作用,可以作为一种潜在的益生菌用于防治嗜水气单胞菌和藤黄微球菌感染

一株有抑菌活性解淀粉芽孢杆菌的鉴定

为了研究环境中芽孢杆菌对常见细菌的抑菌能力,从池塘底泥中分离出6株芽孢杆菌进行了鉴定和抗菌能力研究。以大肠杆菌、金黄色葡萄球菌、藤黄微球菌和嗜水气单胞菌为研究对象,采用管碟法测定了细菌发酵上清液的抑菌活性,测定了发酵上清液和病原菌共培养的生长曲线,并采用生化和16S rRNA基因序列分析对细菌进行鉴定。结果发现其中1个菌株的发酵上清液对嗜水气单胞菌和藤黄微球菌的生长具有抑制作用,进一步通过生化和分子鉴定发现该菌株为解淀粉芽孢杆菌。结果表明:分离的解淀粉芽孢杆菌的发酵产物对嗜水气单胞菌和藤黄微球菌具有抑制作用,可以作为一种潜在的益生菌用于防治嗜水气单胞菌和藤黄微球菌感染

月球水冰资源综合开发技术研究概况

水冰作为月球的重要资源，是未来月球科研站以及月球基地建设和运行的基本保障，开展月球水冰资源综合开发技术研究是目前各航天大国的关注热点之一。本文调研了有关月球水冰的探测和研究成果，阐述了月球水冰的赋存状态与分布特征，详细分析了月球水冰资源在开采提取、分离纯化、储存运输和分解利用等环节的技术方案，并简要评述了各个方案的优缺点。结合中国未来国际月球科研站的建设规划与美国以建立月球基地为目标的阿尔忒弥斯（Artemis）计划，评价分析了适宜开展月球水冰资源综合开发的地区和可行的技术方案，为中国在月球两极地区的水冰资源开发利用方案提供参考

一台用于IMP重离子治癌线上的电离室

介绍一种用于中国科学院近代物理研究所(IMP)重离子肿瘤治疗线上、于纵向场常压下工作的气体电离室,其灵敏面积为250mm×250mm,极间距离为10mm,电离室工作气体为P10,在85kPa下流气式工作。用75MeV/u12C离子入射,测量了电离室的坪曲线。发现电离室工作坪区900—3000V,12C的Bragg峰位于13.73mm,峰的极大值半高宽(FWHM)为0.19mm

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials

JUNO Sensitivity on Proton Decay p→νˉK+p\to \bar\nu K^+ Searches

The Jiangmen Underground Neutrino Observatory (JUNO) is a large liquid scintillator detector designed to explore many topics in fundamental physics. In this paper, the potential on searching for proton decay in $p\to \bar\nu K^+$ mode with JUNO is investigated.The kaon and its decay particles feature a clear three-fold coincidence signature that results in a high efficiency for identification. Moreover, the excellent energy resolution of JUNO permits to suppress the sizable background caused by other delayed signals. Based on these advantages, the detection efficiency for the proton decay via $p\to \bar\nu K^+$ is 36.9% with a background level of 0.2 events after 10 years of data taking. The estimated sensitivity based on 200 kton-years exposure is $9.6 \times 10^{33}$ years, competitive with the current best limits on the proton lifetime in this channel

JUNO sensitivity on proton decay p → ν K + searches*

The Jiangmen Underground Neutrino Observatory (JUNO) is a large liquid scintillator detector designed to explore many topics in fundamental physics. In this study, the potential of searching for proton decay in the $p\to \bar{\nu} K^+$ mode with JUNO is investigated. The kaon and its decay particles feature a clear three-fold coincidence signature that results in a high efficiency for identification. Moreover, the excellent energy resolution of JUNO permits suppression of the sizable background caused by other delayed signals. Based on these advantages, the detection efficiency for the proton decay via $p\to \bar{\nu} K^+$ is 36.9% ± 4.9% with a background level of $0.2\pm 0.05({\rm syst})\pm$$0.2({\rm stat})$ events after 10 years of data collection. The estimated sensitivity based on 200 kton-years of exposure is $9.6 \times 10^{33}$ years, which is competitive with the current best limits on the proton lifetime in this channel and complements the use of different detection technologies